| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8343952 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Aug, 2027
(3 years from now) | |
| US7811595 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Mar, 2028
(3 years from now) | |
Vafseo is owned by Akebia.
Vafseo contains Vadadustat.
Vafseo has a total of 2 drug patents out of which 0 drug patents have expired.
Vafseo was authorised for market use on 27 March, 2024.
Vafseo is available in tablet;oral dosage forms.
The generics of Vafseo are possible to be released after 13 March, 2028.
Drugs and Companies using VADADUSTAT ingredient
Market Authorisation Date: 27 March, 2024
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
VAFSEO family patents
